Contineum Therapeutics, Inc. Class A Common Stock
General ticker "CTNM" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $214.5M (TTM average)
Contineum Therapeutics, Inc. Class A Common Stock follows the US Stock Market performance with the rate: 45.5%.
Estimated limits based on current volatility of 5.2%: low 12.90$, high 14.31$
Factors to consider:
- Total employees count: 41 as of 2024
- Price in estimated range
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2025-12-31 to 2027-12-31
- 2025-12-31 to 2026-12-31 estimated range: [7.67$, 18.99$]
- 2026-12-31 to 2027-12-31 estimated range: [5.39$, 14.14$]
Short-term CTNM quotes
Long-term CTNM plot with estimates
Financial data
| YTD | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|
| Operating Revenue | $50.00MM | $0.00MM | $0.00MM |
| Operating Expenses | $66.08MM | $50.89MM | $68.06MM |
| Operating Income | $-16.08MM | $-50.89MM | $-68.06MM |
| Non-Operating Income | $39.25MM | $8.64MM | $8.08MM |
| Interest Expense | $0.21MM | $0.00MM | $0.00MM |
| R&D Expense | $27.60MM | $38.16MM | $51.52MM |
| Income(Loss) | $23.17MM | $-42.26MM | $-59.98MM |
| Taxes | $0.45MM | $0.00MM | $0.00MM |
| Profit(Loss)* | $22.72MM | $-42.26MM | $-59.98MM |
| Stockholders Equity | $-67.94MM | $198.07MM | $260.99MM |
| Assets | $130.39MM | $212.85MM | $276.64MM |
| Operating Cash Flow | $19.35MM | $-32.84MM | $-55.31MM |
| Capital expenditure | $0.41MM | $0.51MM | $0.23MM |
| Investing Cash Flow | $-65.57MM | $-69.74MM | $-3.71MM |
| Financing Cash Flow | $56.18MM | $109.00MM | $112.69MM |
| Earnings Per Share** | $0.90 | $-2.18 | $-2.17 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.